Clinical Trial

Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments

Study acronym: SPHERA_WP2
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 20, 2024 (before its estimated October 2024 completion). Its status may not reflect the trial's current state.
Summary
Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group. They will be identified as patients showing a reduction of monthly migraine days \< 50% after three months of treatment. The clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients
Trial Details
NCT Number NCT06562400
Lead Sponsor IRCCS National Neurological Institute "C. Mondino" Foundation
Collaborators: University of L'Aquila
Conditions Migraine Disorders, Chronic Migraine, Episodic Migraine
Enrollment 45 participants
Start Date 2023-05-10
Primary Completion 2024-10 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2024-08-20